dabrafenib: Clinical Trials

51 trials of dabrafenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 11 terminated, 6 active not recruiting, 4 withdrawn. 51 Phase 1, 17 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 151Completed 24, Terminated 11, Active not recruiting 6, Withdrawn 4, Recruiting 2, Suspended 2, Unknown 2
Phase 217Completed 9, Active not recruiting 4, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1

Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma
Phase 1 / Phase 2RecruitingAnn & Robert H Lurie Children's Hospital of Chicago272025-04-012026-07-10
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C) - Advanced Solid Tumor, Pancreatic Adenocarcinoma
Phase 1 / Phase 2Active not recruitingImmuneering Corporation2092022-10-312026-10-20
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Dabrafenib, MEK-1/MEKK-1 Inhibitor E6201, Biospecimen Collection - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Phase 1TerminatedMayo Clinic132022-10-202025-08-19
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg - Metastatic Melanoma, BRAF Gene Mutation
Phase 1RecruitingRina Plattner302022-06-012026-02-13
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Phase 1 / Phase 2Active not recruitingNational Cancer Institute (NCI)162021-08-192026-11-18
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib - BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present
Phase 1SuspendedCity of Hope Medical Center62020-09-142026-10-15
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Dabrafenib, LTT462, Trametinib - BRAF V600 Colorectal Cancer
Phase 1TerminatedNovartis Pharmaceuticals1222020-07-222025-12-24
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JSI-1187, Dabrafenib - Solid Tumors
Phase 1SuspendedJS InnoPharm, LLC712020-06-182025-09-03
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Phase 1TerminatedOHSU Knight Cancer Institute22020-04-012024-03-04
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Dabrafenib, Trametinib, Hydroxychloroquine - Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration
Phase 1 / Phase 2Active not recruitingPediatric Brain Tumor Consortium572020-01-172026-09-11
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Trametinib, Dabrafenib, INCB039110 - Melanoma
Phase 1TerminatedMassachusetts General Hospital12019-05-292023-09-22
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
MCS110, Dabrafenib, Trametinib - Melanoma
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute62018-09-102024-07-31
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
E6201, E6201 plus dabrafenib - Malignant Melanoma, Brain Metastases
Phase 1TerminatedSpirita Oncology, LLC42018-07-022022-05-20
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
Dabrafenib, Trametinib, Hydroxychloroquine - Melanoma
Phase 1 / Phase 2UnknownUniversitair Ziekenhuis Brussel632018-01-232021-04-28
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
APR-246, Dabrafenib - Melanoma
Phase 1 / Phase 2TerminatedAprea Therapeutics32018-01-182019-07-31
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib - Melanoma, BRAF Gene Mutation
Phase 1UnknownWest Cancer Center42017-06-252020-10-12
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Dabrafenib, Trametinib - Multiple Myeloma
Phase 1Active not recruitingMassachusetts General Hospital302017-06-212026-07-31
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
Dabrafenib, Trametinib - Melanoma
Phase 1WithdrawnGlaxoSmithKline2017-05-012018-09-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab - Melanoma
Phase 1 / Phase 2CompletedHaukeland University Hospital742017-02-132025-01-14
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Dabrafenib, Trametinib, Phenformin - Melanoma
Phase 1CompletedMemorial Sloan Kettering Cancer Center182017-01-012025-01-23

Showing 20 of 51. Sign in to see all of them.

Conditions studied

Melanoma (27)  ·  Neoplasms (13)  ·  Neoplasm Metastasis (7)  ·  Brain Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colorectal Neoplasms (2)  ·  Glioma (2)  ·  Hematologic Neoplasms (2)  ·  Multiple Myeloma (2)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Renal Insufficiency (2)  ·  Thyroid Carcinoma, Anaplastic (2)  ·  Adenocarcinoma (1)  ·  Anemia (1)  ·  Blast Crisis (1)

Sponsors

GlaxoSmithKline (10)  ·  National Cancer Institute (NCI) (7)  ·  Novartis Pharmaceuticals (7)  ·  Massachusetts General Hospital (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  Aprea Therapeutics (1)  ·  City of Hope Medical Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  Haukeland University Hospital (1)  ·  Immuneering Corporation (1)  ·  JS InnoPharm, LLC (1)  ·  Kartos Therapeutics, Inc. (1)  ·  Manisha Shah (1)  ·  Mayo Clinic (1)

Countries

United States (43)  ·  Australia (10)  ·  United Kingdom (8)  ·  Canada (6)  ·  France (5)  ·  Spain (5)  ·  Belgium (4)  ·  Italy (4)  ·  Germany (3)  ·  Israel (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Denmark (1)  ·  Norway (1)  ·  Poland (1)

Top investigators

Ryan J Sullivan (2)  ·  Ahmad Awada, PhD (1)  ·  Antoni Ribas (1)  ·  Arthur Frankel, MD (1)  ·  Ashley Plant-Fox, MD (1)  ·  Bart Neyns, MD PhD (1)  ·  David M. Miller, MD, PhD (1)  ·  Elizabeth I Buchbinder, MD (1)  ·  Eric J Sherman (1)  ·  Hani M Babiker, MD (1)  ·  Hani M. Babiker, MD (1)  ·  Hussein Tawbi, MD (1)  ·  Jason A Chesney, MD, PhD (1)

Results publications

PMID 36884302, PMID 23645591, PMID 24408395, PMID 24577748, PMID 28879519, PMID 29243287, PMID 29880583, PMID 30181415, PMID 31171878, PMID 31171879, PMID 31506385, PMID 31811016, PMID 33288749, PMID 33762304, PMID 33932130, PMID 34331515, PMID 34801354, PMID 35156519, PMID 36375115, PMID 37042037, PMID 38261444, PMID 39863139, PMID 40721981

NIH funding

U01CA062490 (4), UM1CA186709 (4), P30CA006516 (2), UM1CA186716 (2), 2015 (1), P30CA008748 (1), P30CA015083 (1), R01CA246553 (1), R01CA258751 (1), U01CA069856 (1), U01CA069912 (1), U01CA132123 (1), U01CA132194 (1), U10CA032102 (1), U10CA180830 (1)